LB Pharmaceuticals CEO Heather Turner outlined upcoming clinical milestones for their lead drug LB-102, targeting schizophrenia, bipolar depression, and major depressive disorder with key data expected from late 2027 through mid-2029. The company is conducting Phase 3 trials for schizophrenia with a design aimed at reducing placebo effects and expects robust efficacy based on Phase 2 results. LB-102 aims to differentiate in the large antipsychotic market through rapid onset, safety, and addressing residual symptoms. The company is fully funded through Q2 2029, supporting ongoing trials and potential NDA submissions if Phase 3 is successful.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
